IL10 and cancer: Cancers exploit multiple immunoregulatory pathways to evade elimination by infiltrating, activated tumor-specific T cells, including the production of immunosuppressive cytokines (transforming growth factor-β [TGF-β], interleukin-10 [IL-10]), the expression of immunosuppressive enzymes (indoleamine-2,3-dioxygenase), and the conversion of “normal” APCs and T cells to immunosuppressive cell populations (e.g., regulatory T cells) 26.